RELMADA THERAPEUTICS, INC.
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
On March 24, 2025, pursuant to the Exclusive License Agreement with Trigone, we issued to Trigone 3,017,420 shares of our common stock. The issuance of these shares was exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof as not involving any public offering.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.